Difference between revisions of "Thyroid cancer, BRAF-mutated"
Jump to navigation
Jump to search
m |
m |
||
| Line 11: | Line 11: | ||
|} | |} | ||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
| − | |||
=Differentiated thyroid cancer, all lines of therapy= | =Differentiated thyroid cancer, all lines of therapy= | ||
==Vemurafenib monotherapy {{#subobject:3f8f49|Regimen=1}}== | ==Vemurafenib monotherapy {{#subobject:3f8f49|Regimen=1}}== | ||
| − | + | <div class="toccolours" style="background-color:#eeeeee"> | |
| − | |||
===Regimen {{#subobject:7fb6ac|Variant=1}}=== | ===Regimen {{#subobject:7fb6ac|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 60%; text-align:center;" | {| class="wikitable sortable" style="width: 60%; text-align:center;" | ||
| Line 28: | Line 26: | ||
|} | |} | ||
''Note: this study was in patients with papillary thyroid cancer, only.'' | ''Note: this study was in patients with papillary thyroid cancer, only.'' | ||
| + | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Vemurafenib (Zelboraf)]] 960 mg PO twice per day | *[[Vemurafenib (Zelboraf)]] 960 mg PO twice per day | ||
| − | |||
'''Continued indefinitely''' | '''Continued indefinitely''' | ||
| − | + | </div></div> | |
===References=== | ===References=== | ||
# '''NO25530:''' Brose MS, Cabanillas ME, Cohen EE, Wirth LJ, Riehl T, Yue H, Sherman SI, Sherman EJ. Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016 Sep;17(9):1272-82. Epub 2016 Jul 23. [https://doi.org/10.1016/S1470-2045(16)30166-8 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5532535/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/27460442 PubMed] NCT01286753 | # '''NO25530:''' Brose MS, Cabanillas ME, Cohen EE, Wirth LJ, Riehl T, Yue H, Sherman SI, Sherman EJ. Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016 Sep;17(9):1272-82. Epub 2016 Jul 23. [https://doi.org/10.1016/S1470-2045(16)30166-8 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5532535/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/27460442 PubMed] NCT01286753 | ||
| − | |||
=Anaplastic thyroid cancer, all lines of therapy= | =Anaplastic thyroid cancer, all lines of therapy= | ||
==Dabrafenib & Trametinib {{#subobject:b078c2|Regimen=1}}== | ==Dabrafenib & Trametinib {{#subobject:b078c2|Regimen=1}}== | ||
| − | + | <div class="toccolours" style="background-color:#eeeeee"> | |
===Regimen {{#subobject:e03f2c|Variant=1}}=== | ===Regimen {{#subobject:e03f2c|Variant=1}}=== | ||
{| class="wikitable" style="color:white; background-color:#404040" | {| class="wikitable" style="color:white; background-color:#404040" | ||
| Line 56: | Line 53: | ||
|- | |- | ||
|} | |} | ||
| − | ''Patients in this subgroup had previously treated anaplastic thyroid cancer with BRAF p.V600E mutation.'' | + | ''Note: Patients in this subgroup had previously treated anaplastic thyroid cancer with BRAF p.V600E mutation.'' |
| + | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Dabrafenib (Tafinlar)]] 150 mg PO twice per day | *[[Dabrafenib (Tafinlar)]] 150 mg PO twice per day | ||
*[[Trametinib (Mekinist)]] 2 mg PO once per day | *[[Trametinib (Mekinist)]] 2 mg PO once per day | ||
| − | |||
'''Continued indefinitely''' | '''Continued indefinitely''' | ||
| − | + | </div></div> | |
===References=== | ===References=== | ||
# '''ROAR:''' Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, Wen PY, Zielinski C, Cabanillas ME, Urbanowitz G, Mookerjee B, Wang D, Rangwala F, Keam B. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. J Clin Oncol. 2018 Jan 1;36(1):7-13. Epub 2017 Oct 26. [https://doi.org/10.1200/JCO.2017.73.6785 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791845/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/29072975 PubMed] NCT02034110 | # '''ROAR:''' Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, Wen PY, Zielinski C, Cabanillas ME, Urbanowitz G, Mookerjee B, Wang D, Rangwala F, Keam B. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. J Clin Oncol. 2018 Jan 1;36(1):7-13. Epub 2017 Oct 26. [https://doi.org/10.1200/JCO.2017.73.6785 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791845/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/29072975 PubMed] NCT02034110 | ||
| − | ##'''Update:''' Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, Wen PY, Zielinski CC, Cabanillas ME, Boran A, Ilankumaran P, Burgess P, Romero Salas T, Keam B. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. Ann Oncol. 2022 Apr;33(4):406-415. Epub 2022 Jan 10. [https://doi.org/10.1016/j.annonc.2021.12.014 link to original article] [https://pubmed.ncbi.nlm.nih.gov/35026411/ PubMed] | + | ##'''Update:''' Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, Wen PY, Zielinski CC, Cabanillas ME, Boran A, Ilankumaran P, Burgess P, Romero Salas T, Keam B. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. Ann Oncol. 2022 Apr;33(4):406-415. Epub 2022 Jan 10. [https://doi.org/10.1016/j.annonc.2021.12.014 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc9338780/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/35026411/ PubMed] |
| − | |||
[[Category:Biomarker-specific pages]] | [[Category:Biomarker-specific pages]] | ||
[[Category:Thyroid cancer regimens]] | [[Category:Thyroid cancer regimens]] | ||
[[Category:Endocrine cancers]] | [[Category:Endocrine cancers]] | ||
[[Category:Head and neck cancers]] | [[Category:Head and neck cancers]] | ||
Revision as of 12:14, 27 February 2023
Section editor transclusions Note: these are regimens tested in biomarker-specific populations, please see the main thyroid cancer page for other regimens.
2 regimens on this page
2 variants on this page
|
Differentiated thyroid cancer, all lines of therapy
Vemurafenib monotherapy
Regimen
| Study | Years of enrollment | Evidence |
|---|---|---|
| Brose et al. 2016 (NO25530) | 2011-2013 | Phase 2 |
Note: this study was in patients with papillary thyroid cancer, only.
References
- NO25530: Brose MS, Cabanillas ME, Cohen EE, Wirth LJ, Riehl T, Yue H, Sherman SI, Sherman EJ. Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016 Sep;17(9):1272-82. Epub 2016 Jul 23. link to original article contains dosing details in manuscript link to PMC article PubMed NCT01286753
Anaplastic thyroid cancer, all lines of therapy
Dabrafenib & Trametinib
Regimen
| FDA-recommended dose |
| Study | Years of enrollment | Evidence | Efficacy |
|---|---|---|---|
| Subbiah et al. 2017 (ROAR) | 2014-2016 | Phase 2, <20 pts in subgroup (RT) | ORR: 63% (95% CI, 35-85) |
Note: Patients in this subgroup had previously treated anaplastic thyroid cancer with BRAF p.V600E mutation.
Targeted therapy
- Dabrafenib (Tafinlar) 150 mg PO twice per day
- Trametinib (Mekinist) 2 mg PO once per day
Continued indefinitely
References
- ROAR: Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, Wen PY, Zielinski C, Cabanillas ME, Urbanowitz G, Mookerjee B, Wang D, Rangwala F, Keam B. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. J Clin Oncol. 2018 Jan 1;36(1):7-13. Epub 2017 Oct 26. link to original article contains dosing details in manuscript link to PMC article PubMed NCT02034110
- Update: Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, Wen PY, Zielinski CC, Cabanillas ME, Boran A, Ilankumaran P, Burgess P, Romero Salas T, Keam B. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. Ann Oncol. 2022 Apr;33(4):406-415. Epub 2022 Jan 10. link to original article link to PMC article PubMed